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ABSTRACT
ZNF509 is unique among POK family proteins in that
four isoforms are generated by alternative splicing.
Short ZNF509 (ZNF509S1, -S2 and -S3) isoforms con-
tain one or two out of the seven zinc-fingers con-
tained in long ZNF509 (ZNF509L). Here, we investi-
gated the functions of ZNF509 isoforms in response
to DNA damage, showing isoforms to be induced by
p53. Intriguingly, to inhibit proliferation of HCT116
and HEK293 cells, we found that ZNF509L activates
p21/CDKN1A transcription, while ZNF509S1 induces
RB. ZNF509L binds to the p21/CDKN1A promoter ei-
ther alone or by interacting with MIZ-1 to recruit the
co-activator p300 to activate p21/CDKN1A transcrip-
tion. In contrast, ZNF509S1 binds to the distal RB
promoter to interact and interfere with the MIZF re-
pressor, resulting in derepression and transcription
of RB. Immunohistochemical analysis revealed that
ZNF509 is highly expressed in normal epithelial cells,
but was completely repressed in tumor tissues of the
colon, lung and skin, indicating a possible role as a
tumor suppressor.
INTRODUCTION
There are nearly 200 human BTB/POZ domain-containing
proteins. BTB/POZ domain proteins having one or more
Kru˝ppel-like zinc-fingers are classified as the POK fam-
ily. The N-terminal POZ domain has an important role in
forming homo- or hetero-dimers and interacting with other
proteins, while the C-terminal Kru˝ppel-like zinc-finger do-
main (C2H2) recognizes and binds to specific DNA se-
quences (1–4). POK family proteins that have been rela-
tively well characterized include B-cell CLL/lymphoma 6
(BCL6), factor binding IST protein-1 (FBI-1)/leukemia-
/lymphoma-related factor, hypermethylated in cancer 1
(HIC1), promyelocytic leukemia zinc-finger (PLZF) and
Myc-interacting zinc-finger-1 (MIZ-1).
Aberrant expression of some POK family proteins, in-
cluding BCL6, FBI-1 and HIC1, has been associated with
cancers, such as leukemia and various spontaneous ma-
lignant tumors (5–8). PLZF controls the development of
invariant natural killer T cell effector function and the
maintenance of spermatogonial stem cells (9,10). MIZ-1,
a potent transcriptional activator of CDKN1A (11), in-
teracts with various oncoproteins, such as c-MYC, BCL6,
ZBTB4 and GFI-1, to repress transcription of genes in-
volved in cellular differentiation and metabolism (6,11–13).
Recently, some novel POK family proteins have been char-
acterized as transcriptional regulators of genes that control
cell proliferation (14–20). Although POK family proteins
appear to play key roles in the various cell regulatory pro-
grams described above, the functions of many of the above-
mentioned POK family proteins remain largely unknown
(3).
The retinoblastoma (Rb) protein and p53 are two main
tumor suppressors that control cellular responses to po-
tentially oncogenic stimuli, including repeated rapid cell
division, DNA damage and inappropriate mitogenic sig-
nals (21). The tumor suppressor p53 mediates several cel-
lular stress responses, including cell-cycle arrest, apoptosis
and genomic stability, by inducing the transcription of var-
ious target genes (22–24). Normally, p53 is short-lived and
present at low levels. However, in response to a variety of
genotoxic stresses, p53 is activated or stabilized by phos-
phorylation and acetylation by interacting with kinases and
acetyltransferases (23–25). Genes activated by p53 include
a negative cell-cycle regulator, CDKN1A (p21), and pro-
apoptotic genes, such as BAX and PUMA (22,23,26). In
particular, CDKN1A is a negative regulator of G0-G1, S
and M cell-cycle phase checkpoints, and is mainly regu-
lated at the transcriptional level by various oncogenes, tu-
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mor suppressors and cellular regulators (27–29). The ability
of p21 to inhibit proliferation may contribute to its tumor
suppressor function, and a number of oncoproteins, such
as BCL6, FBI-1, ZBTB2 and KR-POK repress CDKN1A,
thus promoting cell growth and tumorigenesis (6,15,17,30).
In contrast, the potential tumor suppressor MIZ-1 was
shown to inhibit cell proliferation by transcriptional acti-
vation of CDKN1A (11).
The importance of the Rb protein in cancer was first sug-
gested by the finding that anRB allele was invariably deleted
in retinoblastoma (31–33). Rb regulates normal cell-cycle
progression and stress responses. Cell-cycle progression is
directly controlled by a series of cyclin-dependent kinases
(CDKs) that bind to and phosphorylate their respective cy-
clins. The cycle starts in G1 with elevated levels of cyclin
D, which activates CDK4 and CDK6. The activated cy-
clin D-CDK4/6 complex then phosphorylates Rb, which
is also important for regulating E2F activity (34,35). In
its hypophosphorylated state, Rb forms a stable complex
with E2F1, preventing it from inducing transcription of
cell-cycle progression genes. Phosphorylation of Rb by
CDK4/6 disrupts complex formation with E2F, which can
then dimerize with various transcription factor partners
and activate a number of target genes thought to promote
entry into S phase, including cyclins E and A (34–36). In-
vestigations of how and which regulatory proteins control
RB transcription are important in elucidating the cellular
regulatory function of Rb, as well as induction of its target
genes MYOD, GABP and HCF-1 in cell-cycle arrest and
myogenesis (37,38). In contrast, YY1, MIZF and FBI-1 re-
press transcription of RB, and this repression is important
for increasing cell proliferation and inhibiting myogenesis
(38–40).
Over the years, we found that some POK family proteins
play important roles in cell-cycle regulation. We were par-
ticularly interested in a novel member of the POK tran-
scription factor family, ZNF509, due to its interaction with
many other POK proteins (unpublished data) and thus its
likely important roles in various cellular processes. We also
noted that ZNF509 transcription is induced by the DNA-
damaging agent etoposide, and suspected that ZNF509may
thus play a critical role in DNA damage responses. Specif-
ically, we found that ZNF509 isoforms are induced in p53-
positive cells exposed to genotoxic stress and that ZNF509
expression is dysregulated in cancer tissues. In the current
study, we characterized ZNF509, finding that two major
ZNF509 isoforms are induced by p53 and act as down-
stream executioners of cell-cycle arrest by inducing expres-
sion of p21 and RB.
MATERIALS AND METHODS
Cell culture and transient transfection assays
HEK293, HCT116 p53+/+ and HCT116 p53−/− cells were
maintained in Dulbecco’s modified Eagle’s medium, sup-
plemented with 10% fetal bovine serum (FBS), 100 g/ml
streptomycin and 100 units/ml penicillin and grown at 37◦C
in a humidified, 5% CO2 incubator. All cell culture media
and supplements were from Gibco-BRL.
Various combinations of the plasmids pGL2-ZNF509-
Luc, pGL3-RB-Luc, pGL2-ARF-Luc, pGL2-HDM2-
Luc, pGL2-p53-Luc, various pGL2-CDKN1A-Luc
promoter reporters, pcDNA3.0-ZNF509L, pcDNA3.0-
ZNF509S1, pcDNA3.1-MIZ-1, pcDNA3.1-MIZF, HA-
p300, pcDNA3.1-p53, pcDNA3.1-p53R175H, pcDNA3.1-
p53R248W, pcDNA3.1-p53R273H and pCMV-LacZ
were transiently transfected into HEK293, HCT116
p53+/+ or HCT116 p53−/− cells using Lipofectamine Plus
reagent (Invitrogen, Carlsbad, CA, USA). After 24–36
h of incubation, transfected cells were harvested and
analyzed for luciferase activity using a Microplate LB
96V luminometer (EG&G Berthold). All reactions were
performed in triplicate. Reporter activity was normalized
to co-transfected -galactosidase activity, or total cellular
protein, to determine transfection efficiencies.
Foci formation assay
HEK293 and HCT116 p53+/+ cells were cultured in 6-well
culture plates and then transfected with 0.5 g pcDNA3.0
and pcDNA3.0-ZNF509L or -S1 using Lipofectamine plus
reagent (Invitrogen). Following transfection, cells were se-
lected in a medium supplemented with 10% FBS for 1 week
in the presence of G418 (800 g/ml). Colonies resistant to
G418 were stained with crystal violet (0.5% crystal violet in
20% EtOH).
MTT assay
To investigate the effect of ZNF509 on cell proliferation,
cells were grown in 24-well dishes to 30∼50% confluency
and incubated for 0–3 days. The cell growth of each sample
was determined by measuring mitochondrial conversion of
the tetrazolium salt MTT to formazan.
Flow cytometry cell-cycle analysis
Cells were fixed with 70% ethanol and washed with PBS
containing 1% horse serum, and cellular DNA was stained
with propidium iodide (100 g/ml). Cell cycle and forward
scatter profiles were determined using a Becton Dickinson
FACSCalibur, as analyzed by ModFit LT 2.0 (Verity Soft-
ware House, Inc.).
Quantitative reverse transcriptase-polymerase chain reaction
(RT-qPCR)
Quantitative RT-PCR reactions were conducted with
SYBR Green PCR Master Mix (Applied Biosystems) us-
ing gene-specific primers in an ABI PRISM 7300 RT-PCR
System. All reactions were performed in triplicate. GAPDH
(glyceraldehyde-3-phosphate dehydrogenase) mRNA was
measured as a control. The following RT-qPCR oligonu-
cleotide primers sets were used: ZNF509 (forward, 5′-
AGATGGCAGCTGCACAGAACTGCCTTT-3′; reverse,
5′-GGGACCAGCTGCGTGTTTAT-3′), MIZ-1 (forward,
5′-AGACCCACGACACGGACAA-3′; reverse, 5′-CCG
TCAGCGATGTGGATCT-3′), p53 (forward, 5′-CCTGA
GGTTGGCTCTGACTGTA-3′; reverse, 5′-AAAGCTG
TTCCGTCCCAGTAGA-3′), p21 (forward, 5′-AGGGG
ACAGCAGAGGAAG-3′; reverse, 5′-GCGTTTGGAGT
GGTAGAAATCTG-3′), MIZF (forward, 5′-GTGTCTG
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TGGGAGCACTGTGA-3′; reverse, 5′-TGCTTCCACAT
GCCGATAAA-3′), RB (forward, 5′-AAAGAAAAAGG
AACTGTGGG-3′; reverse, 5′-AACTGCTGGGTTGTG
TCAAA-3′), GAPDH (forward, 5′-CCCCTTCATTGAC
CTCAACTAC-3′; reverse, 5′-TCTCGCTCCTGGAAG
ATGG-3′).
Western blot analysis
Cells were harvested and lysed in radioimmunoprecipita-
tion assay (RIPA) buffer. Cell extracts (30 g) were sepa-
rated using 12% sodium dodecyl sulphate-polyacrylamide
gel electrophoresis (SDS-PAGE), transferred onto Immun-
Blot polyvinylidene difluoride (PVDF) membranes (Bio-
Rad) and blocked with 5% skim milk (BD Biosciences) or
bovine serum albumin. Membrane blots were then incu-
bated with antibodies against GAPDH, FLAG, c-Myc, His,
p53, p21, Rb, p300, MIZ-1, MIZF and ZNF509, followed
by incubation with anti-mouse or rabbit secondary anti-
bodies conjugated to Horseradish peroxidase (Vector Lab-
oratories). Protein bands were visualized using an ECL kit
(PerkinElmer Life Sciences).
GST-fusion protein purification and GST pull-down assays:
in vitro transcription and translation of p300
Recombinant GST, GST-POZZNF509, GST-ZFZNF509L,
GST-ZNF509L and GST-ZNF509S1 fusion proteins
were prepared from Escherichia coli BL21 (DE3) cells
by glutathione-agarose 4 bead affinity chromatography
(Peptron). p300 polypeptide fragments were prepared in
vitro using transcription and translation (TNT)-coupled
wheat germ extracts in the presence of [35S]-methionine
(Promega). GST-fusion protein-agarose bead complexes
were then incubated with the labeled p300 polypeptide
fragments at 4◦C for 4 h in 25 mM HEPES, pH 7.6,
0.5 mM EDTA, 12.5 mM MgCl2, 10% glycerol, 1 mM
dithiothreitol and 0.2 mM phenylmethylsul fonyl fluoride
(HEMG) buffer. Other GST protein pull-down procedures
were performed as we have previously reported (15).
Co-immunoprecipitation
Cells were washed, pelleted and resuspended in a lysis buffer
supplemented with complete mini-protease inhibitor cock-
tail. Cell lysates or recombinant proteins were pre-cleared
and supernatants incubated overnight with antibodies at
4◦C, followed by the addition of proteinA/Gagarose beads,
as reported previously (15).
Electrophoretic mobility shift assays (EMSAs)
For EMSAs, oligonucleotide probes were annealed by heat-
ing at 95◦C for 5 min and slowly cooled to room tempera-
ture. Annealed oligonucleotides were then labeled with [-
32P]-ATP and Klenow enzyme (Roche) by incubating for
30 min at 37◦C, and purified using Sephadex G-50 (Amer-
sham Biosciences) columns. Binding reactions were con-
ducted in 20 l binding buffer with labeled probes and pu-
rified recombinant GST-ZFZNF509 (200 ng). The remain-
ing EMSA procedures have been reported elsewhere (15).
The EMSA probe sequences of theCDKN1A proximal pro-
moter GC box elements were as follows (only the top strand
is shown):GCbox#1, 5′-TTGGGAGGGCGGTCCCG-3′;
GC box#3, 5′-TTCGAGCGCGGGTCCCGCCTC-3′; GC
box #5/6, 5′-TTGGGCGGGGCGGTTGTATATCA-3′.
Oligonucleotide pull-down assays
Cells were lysed in HKMG (10 mM HEPES, pH 7.9,
100 mM KCl, 5 mM MgCl2, 10% glycerol, 0.1% NP-
40 and 1 mM dithiothreitol) buffer and the extracts in-
cubated with 1 g biotinylated double-stranded oligonu-
cleotides for 16 h. Oligonucleotide probes were annealed
by heating at 95◦C for 5 min, cooled slowly to room
temperature and pull-down procedures performed as re-
ported elsewhere (15,46). Oligonucleotides sequences were
(only top strands are shown): ZNF509 promoter p53RE,
5′-TAACATGCCCTTAGGTTTGGTT-3′; MT p53RE, 5′-
TAAGGGGCCCTTAGGGGGGGTT-3′. CDKN1A pro-
moterGC box #1, 5′-GATCGGGAGGGCGGTCCCG-3′;
GC box #2, 5′-GATCTCCCGGGCGGCGCG-3′; GC box
#3, 5′-GATCCGAGCGCGGGTCCCGCCTC-3′; GC box
#4, 5′-GATCCTTGAGGCGGGCCCG-3′; GC box #5/6,
5′-GATCGGGCGGGGCGGTTGTATATCA-3′.
Chromatin immunoprecipitation (ChIP) and ChIP-reChIP
Cells were fixed with formaldehyde (final 1%) to cross-
link proteins to DNA promoters. ChIP and ChIP-
reChIP procedures were then performed as reported else-
where (20). For detection of transcription factor bind-
ing, chromatin was immunoprecipitated with antibod-
ies against p53, FLAG-tag, His-tag and Myc-tag. Im-
munoglobulin G (IgG) and 3′-untranslated region (UTR)
were used as negative controls. PCR reactions were con-
ducted using the following oligonucleotide primer sets de-
signed to amplify the regions of interest: ZNF509 pro-
moter (forward, 5′-AGCTTCATCCCTGCCCAATTGT
A-3′; reverse, 5′-TTGAATAAGTAATACAAAAATAT-
3′), ZNF509 3′-UTR (forward, 5′-TGCCTTCTAACTAG
CCAGAGAAT-3′; reverse, 5′-AAATGCTACAAATTTC
AATCTTG-3′). CDKN1A distal promoter (forward, 5′-
TGCTTGGGCAGCAGGCTGTG-3′; reverse, 5′-GCAA
CCATGCACTTGAATGT-3′), CDKN1A proximal pro-
moter (forward, 5′-GCGCTGGGCAGCCAGGAGCC-
3′; reverse, 5′-CGCTCTCTCACCTCCTCT-3′). RB dis-
tal promoter (forward, 5′-CACTAGCCAGATATTCCC
TGCGGGG-3′; reverse, 5′-TAAGTCATGAGGAATTAA
ACTGGGA-3′), RB proximal promoter (forward, 5′-CA
CCGACCAGCGCCCCAGTTCCCCA-3′; reverse, 5′-GG
GAGGACGCGCGCGCACGTCG-3′), RB 3′-UTR (also
used for qChIP) (forward, 5′-GGATCTCAGGACCTTG
GTGG-3′; reverse, 5′-AGGGCCATTCTTACTATCCA-
3′).
For quantitative ChIP assays, the following qChIP
oligonucleotide primers sets were used: CDKN1A proximal
promoter (forward, 5′-GATCGCTACCGCGCTGGGCA
GCCAGGAGCCT-3′; reverse, 5′-TCGTCACCCGCGCA
CTTAGA-3′), CDKN1A 3′-UTR (forward, 5′-GTCACC
CTGCCCAACCTTAG-3′; reverse, 5′-TCCTTCCCATCG
CTGTCACA-3′). IgG and 3′-UTR were used as negative
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controls for the ChIP assays. All reactions were performed
in triplicate.
Histology and immunohistochemistry
Histological analyses were carried out by following a stan-
dard protocol. Formaldehyde-fixed paraffin-embedded tis-
sue sections were purchased from Accumax Array (ISU
ABXIS) and Biomax (US Biomax). DAB immunohisto-
chemical (IHC) staining was done according to the man-
ufacturer’s instructions (VECTASTAIN ABC Kit, Vec-
tor Laboratories) after incubating with ZNF509 antibody
overnight at 4◦C.
Statistical analysis
Student’s t-test was used for statistical analyses.
RESULTS
ZNF509 is a novel POK family protein and there are four
ZNF509 isoforms differing in the C-terminal zinc-finger re-
gion
The human genomic sequence encoding ZNF509 protein
maps to chromosome 4p16.3, and ZNF509 cDNA (Gene
ID: 166793) encodes a protein comprised of 765 amino
acids (GenBank Accession No. NP 660334.3, Supplemen-
tary Figure S1A). We were interested in ZNF509 because it
is one POK family member that interacts with many other
POK proteins (unpublished data), implying it has impor-
tant roles in cellular processes. We also noted that ZNF509
transcription was induced by the DNA-damaging agent
etoposide. To study the biological function of ZNF509, we
tried to clone a human ZNF509 cDNA into a mammalian
expression vector, pcDNA3.0. Initially, we designed PCR
amplification primers based on the full-length open reading
frame (ORF) mRNA sequence (NCBI # NM 145292.3).
Upon agarose gel electrophoresis of the amplified PCR
products, we noted a band smaller than the full-lengthORF
(Supplementary Figure S2D). This observation led us to
suspect that there may be two or more transcripts coming
from the ZNF509 gene. Indeed, cloning and sequencing of
the PCRproducts suggested four alternatively spliced forms
of the ZNF509 primary transcript: ZNF509L, encoding a
polypeptide of 765 amino acid (a.a.), ZNF509S1 or -S2, en-
coding 420 a.a. polypeptides and ZNF509S3, encoding a
466 a.a. polypeptide (Supplementary Figure S2C). Anal-
ysis of ZNF509 genomic DNA sequence revealed splic-
ing donor and acceptor sites needed to generate four al-
ternatively spliced mRNA transcripts (Supplementary Fig-
ure S2A, B and E). Transcripts encoding ZNF509L, -S1
and -S2 were abundant, but ZNF509S3 mRNA was rather
scarce. ZNF509S1 and S2 mRNA encoded essentially iden-
tical proteins of 420 a.a., differing only at a.a. 420 (S1,
Asn; S2, Arg). ZNF509S1 possessed an additional 123 nu-
cleotides, compared to ZNF509S2, posterior to the trans-
lation stop codon. Based on these results, we further inves-
tigated the functions of ZNF509L and -S1, the two major
forms of protein products encoded by the ZNF509 gene.
ZNF509 has isoforms that are downstream targets induced
by p53
We first analyzed the expression of ZNF509 isoforms in the
HEK293 cells treated with etoposide. Etoposide treatment
increased endogenous p53 expression and also ZNF509 ex-
pression at both its mRNA and protein levels (Figure 1A).
Interestingly, ZNF509 expression wasmore prominently in-
creased in HCT116 p53+/+ than in HCT116 p53−/− cells by
etoposide treatment. InHCT116 p53+/+ cells, the ZNF509L
and -S isoforms were induced by 3.95- and 3.53-fold, re-
spectively. InHCT116 p53−/− cells, however, ZNF509L and
-S were induced by only 1.9- and 2.07-fold, respectively
(Figure 1B, right). It appeared that etoposide elicited post-
translational control of ZNF509L and -S expression, with
a lack of transcriptional activation of ZNF509L and -S in
HCT116 p53−/− cells (Figure 1B, center).
Because etoposide treatment can only activate ZNF509
gene transcription in HCT116 p53+/+ cells, but not in
HCT116 p53−/− cells,ZNF509may be a downstream target
of p53. We further showed that wild type, but not mutated
p53 could activateZNF509 (Figure 1C).ZNF509 promoter
analysis further revealed two potential p53-response ele-
ments (p53REs) that bind p53. We next cloned theZNF509
promoter (bp, −2000 ∼ +50) fragment, containing two pu-
tative p53REs at bp, −1803 ∼ −1782 region, in front of lu-
ciferase gene of the pGL2-Luc plasmid. In HCT116 p53−/−
cells, ectopic p53 only weakly activated ZNF509 promoter-
driven reporter transcription, suggesting the presence of
other p53REs elsewhere (Supplementary Figure S4). ChIP
showed that endogenous p53 binds to the putative p53RE
region (Figure 1D). Oligonucleotide pull-down assays fur-
ther showed that p53 bound to the wild type, but not mu-
tant, p53RE in the ZNF509 promoter (Figure 1E). These
data overall suggest that p53 induced by etoposide treat-
ment can bind to p53RE on the ZNF509 promoter and ac-
tivate ZNF509 gene transcription, leading to expression of
both the ZNF509L and -S isoforms.
ZNF509L inhibits cell proliferation by transcriptional activa-
tion of CDKN1A, increasing the G2-M cell-cycle phase cell
population
SAGE (serial analysis of gene expression) analysis by
CGAP (the Cancer Genomic Anatomy Project: http://
cgap.nci.nih.gov/SAGE) showed that ZNF509 expression
is lower in most cancer tissues from breast, pancreas,
ovary, prostate and skin, as compared to its expression
in normal tissues. Consequently, we investigated whether
ZNF509L could regulate the proliferation of HEK293 and
HCT116 p53+/+ cells. Ectopic ZNF509L inhibited both cell
growth and foci formation (Figure 2A; Supplementary Fig-
ure S5A). Conversely,MTT assays showed that knockdown
of ZNF509 increased cell proliferation (Figure 2B; Supple-
mentary Figure S5B). Flow cytometry analysis further re-
vealed that ectopic ZNF509L increased cells inG2-Mphase
(14.0–30.4%), while knockdown of ZNF509L and -S by
siZNF509RNA increased cells in S phase (7.8–26.8%) (Fig-
ure 2C; Supplementary Figure S5C).
Because ZNF509L inhibited cell proliferation, we next
investigated whether ZNF509L regulates expression of RB,
ARF, HDM2, TP53 and CDKN1A, important cell-cycle
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Figure 1. p53 activates transcription of ZNF509. (A) RT-qPCR and western blot analysis of ZNF509. HEK293 cells were treated with etoposide in either
a time- or dose-dependent manner. (B) RT-qPCR and western blot analysis of endogenous ZNF509 in HCT116 p53+/+ and p53−/− cells treated with
etoposide (5 M). (C) RT-qPCR and western blot analysis of endogenous ZNF509 in HCT116 p53−/− cells transfected with p53 wild-type and mutant
expression vectors. (D) ChIP assay of p53 binding to the potential p53RE (bp, -1803 ∼ -1782) of the endogenous ZNF509 promoter. (E) Oligonucleotide
pull-down/western blot assay of p53 binding to the wild-type and mutant p53RE shown below. p53RE, p53 response element; GAPDH, control; 3′-UTR,
3′-untranslated region; IP, immunoprecipitation; DNA-P, oligonucleotide pull-down assay. *P < 0.01; n.s., not significant.
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Figure 2. ZNF509L induces cell-cycle arrest in HCT116 p53+/+ cells. (A) Foci formation assay. Cells transfected with a control pcDNA3.0 (upper row) or
FLAG-ZNF509L expression (lower row) vector were cultured in medium containing G418 and stained with 0.1% crystal violet. (B) MTT assay of cells
grown for 0–3 days. Cells were transfected with either control or ZNF509L expression vectors and analyzed for cell growth (left). Alternatively, cells were
transfected with ZNF509 siRNA (right). (C) Flow cytometry analysis. Cells were transfected with ZNF509L expression vector or ZNF509 siRNA for 24 h,
stained with propidium iodide, and analyzed by FACS. (D)RT-qPCR and western blot analysis of endogenous p21 expression in the HCT116 p53+/+ cells
transfected with a ZNF509L expression vector. (E)RT-qPCR and western blot analysis of endogenous p21 expression in HCT116 p53+/+ cells transfected
with ZNF509 siRNA. (F and G) RT-qPCR and western blot analysis of endogenous p53 (F; HCT116 p53+/+ cells) or p21 (G; HCT116 p53−/− cells). The
cells were transfected with a ZNF509L expression vector. GAPDH, control; Mock, no siRNA; N.C., negative control scrambled siRNA. *P < 0.01; n.s.,
not significant.
regulators. Reporter assays showed that ZNF509L acti-
vated theCDKN1A promoter inHEK293 cells (Supplemen-
tary Figure S6A), and also increased endogenous p21 ex-
pression. Conversely, knockdown of endogenous ZNF509L
decreased CDKN1A transcription (Figure 2D and E; Sup-
plementary Figure S6B and C). Transient transcription as-
says further indicated that ZNF509L appears to weakly
activate TP53 transcription and in turn, p53 might con-
tribute to transcriptional activation of CDKN1A. However,
RT-qPCR and western blot analysis of endogenous p53 in
HCT116 p53+/+ cells showed that ZNF509L did not change
endogenous p53 expression at either the mRNA or protein
levels (Figure 2F). We thus investigated whether ZNF509L
could induce CDKN1A independent of p53, showing that
in HCT116 p53−/− cells transfected with ZNF509L expres-
sion vector,CDKN1A transcription increased robustly (Fig-
ure 2G).
ZNF509L binds CDKN1A promoter GC boxes #3 and 5/6
and interacts directly with p300
We mapped the cis-regulatory elements of the CDKN1A
promoter important for transcriptional activation by
ZNF509L. Transcription assays using four different
promoter-Luc fusion reporter plasmids, combined with
ChIP assays of endogenous CDKN1A, indicated that
ZNF509L activates transcription by acting on a proximal
promoter element (Figure 3A and B). Fine mapping
analysis by oligonucleotide pull-down and EMSA further
showed that ZNF509L binds to the CDKN1A proximal
promoter GC boxes #3 and 5/6 (Figure 3C–E), suggesting
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Figure 3. ZNF509L binds to the proximal GC boxes #3 and 5/6 and interacts with p300 to activate the CDKN1A promoter. (A) Transient transcription
analysis of variousCDKN1A promoter luciferase gene fusion constructs. ZNF509L expression vector and reporter plasmids were transiently co-transfected
and luciferase activity was measured. Error bars represent standard deviations. (B) ChIP assay of ZNF509L binding to the CDKN1A promoter. HCT116
p53+/+ cells were transfected with a FLAG-ZNF509L expression vector and immunoprecipitated with anti-FLAG antibody. (C and D) Oligonucleotide
pull-down assays of ZNF509L binding to the proximal promoter elements of CDKN1A. HEK293 cell extracts with ectopic FLAG-ZNF509L expression
were incubated with oligonucleotides, NeutrAvidin-agarose beads and precipitated by centrifugation. The precipitate was analyzed by western blot using
an anti-FLAG antibody. (E) EMSA. A 32P-labeled GC box #1, 3 and 5/6 probe was incubated with GST-ZFZNF509L and separated by 4% non-denaturing
PAGE. The gel was then analyzed by autoradiography. (F) Co-immunoprecipitation of ZNF509L and HAT proteins (p300, Tip60 and PCAF). Cell lysates
prepared from HEK293 cells transfected with a FLAG-ZNF509 expression vector were immunoprecipitated using anti-FLAG antibody, and further
analyzed by western blot using the anti-HAT antibodies indicated. (G) Co-immunoprecipitation of in vitro protein–protein interaction mixture containing
recombinantHis-ZNF509L and/or FLAG-p300 proteins. Themixtures were immunoprecipitated using anti-His or anti-FLAGantibodies, and analyzed as
described above. (H)ChIP assays of p300 binding and histone modifications within theCDKN1A proximal promoter using antibodies against p300, Ac-H3
and Ac-H4. HCT116 p53+/+ cells were transfected with FLAG-ZNF509L or siZNF509 RNA and immunoprecipitated using the antibodies indicated. (I)
Transcriptional regulation of theCDKN1A promoter by ZNF509L and p300. Expression vectors containing ZNF509L and/or p300 and reporter plasmids
were transiently co-transfected in HEK293 cells and luciferase activity was measured. Error bars represent standard deviations. GAPDH, control; 3′-UTR,
3′-untranslated region; IP, immunoprecipitation; DNA-P, oligonucleotide pull-down assay. *P < 0.01.
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the GC boxes of the proximal promoter are important for
transcriptional activation of CDKN1A by ZNF509L.
Transcriptional activators often interact with co-
activators, such as p300/CBP, PCAF and Tip60 (41–44).
To examine this possibility for ZNF509L, we performed
co-immunoprecipitation and western blot analysis of
HEK293 cell extracts transfected with the FLAG-
ZNF509L expression vector using anti-p300, anti-PCAF
and anti-Tip60 antibodies. These assays showed that
p300 and Tip60 proteins both interact with ZNF509L,
but not PCAF (Figure 3F). We prepared recombinant
proteins (FLAG-p300 or His-ZNF509L) and carried
out immunoprecipitation/western blot assays, and were
able to demonstrate direct protein interaction between
ZNF509L and p300 (Figure 3G). GST-fusion protein
pull-down assays further showed that the POZ and the
ZF domain of ZNF509L interact directly with the HAT
domain of p300 (Supplementary Figure S7). ChIP assays
further showed increased binding of p300 to the CDKN1A
proximal promoter in the presence of ectopic ZNF509L;
in contrast, knockdown of ZNF509 expression decreased
p300 binding. ZNF509L and p300 synergistically induced
CDKN1A in HEK293 cells by increasing acetylation of
nucleosomal histones H3 and H4 within its proximal
promoter, as revealed by ChIP (Figure 3H and I).
ZNF509L and MIZ-1 additively activate CDKN1A tran-
scription
Because ZNF509L by itself only moderately upregulated
CDKN1A, we searched for additional transcription fac-
tors that might potentiate ZNF509L induction activity. Our
BTB/POZ protein interaction network mapping study (un-
published data) of POK family proteins showed that, via
its POZ domain, ZNF509L interacts with MIZ-1 (a well-
known CDKN1A activator), which had the highest amino
acid sequence homology to the ZNF509 POZ domain (Fig-
ure 4A). Co-immunoprecipitation andwestern blot analysis
of HCT116 p53+/+ cells transfected with FLAG-ZNF509L
expression vector showed that ZNF509L and MIZ-1 in-
teract with each other (Figure 4B; Supplementary Fig-
ure S8A). Mechanistically, ChIP and oligonucleotide pull-
down assays showed that MIZ-1 considerably increased
ZNF509L binding to the CDKN1A proximal promoter,
and ChIP-reChIP assays confirmed that ZNF509L forms a
complex withMIZ-1 on theCDKN1A promoter (Figure 4C
and D; Supplementary Figure S8B).
RT-qPCR and western blot analysis further showed that
while ZNF509L and MIZ-1 each activated CDKN1A tran-
scription independently, and knockdown of each protein
alone decreased p21 expression, knockdown of both pro-
teins decreased p21 expression even further (Figure 4E). Co-
expression of the two proteins resulted in additive transac-
tivation of endogenous CDKN1A and a reporter (Supple-
mentary Figures S8C and S9A). In line with transcription
data, MTT and fluorescence-activated cell sorting (FACS)
analysis showed that cells expressing ectopic ZNF509L
and/or MIZ-1 showed slow growth or G2/M growth ar-
rest (Supplementary Figure S9B and C). In the presence of
the two interacting proteins, the transactivation potential of
p300 was maximized (Supplementary Figure S9D).
ZNF509S1 induces cell-cycle arrest by transcriptional acti-
vation of RB
As shown in Figure 1A, etoposide treatment induced p53,
followed by upregulation of the ZNF509 isoforms. Since
ZNF509L can cause cell-cycle arrest via CDKN1A acti-
vation, we also investigated whether ZNF509S1 could do
likewise. Cells expressing ectopic ZNF509S1 grew slowly
and formed few foci, similar to cells ectopically express-
ing ZNF509L (Figure 5A; Supplementary Figure S10A).
Similarly, MTT assays also showed that ectopic ZNF509S1
expression inhibited cell proliferation (Figure 5B; Supple-
mentary Figure S10B). We performed cell-cycle flow cy-
tometry analysis in cells with ectopic ZNF509S1 expres-
sion. In contrast to ZNF509L, which primarily increased
the G2-M phase population, ZNF509S1 prominently in-
creased the G0-G1 population, in addition to the G2-M
population (Figure 5C). Because ZNF509S1 arrests cell cy-
cle, we investigated whether ZNF509S1 could regulate the
important cell-cycle regulators RB, ARF, HDM2, TP53
and CDKN1A. Reporter assays showed that ZNF509S1
also upregulated RB in HEK293 cells (Supplementary Fig-
ure S11A), while cells transfected with a ZNF509S1 expres-
sion vector showed increased endogenous Rb expression at
both the mRNA and protein levels (Figure 5D; Supplemen-
tary Figure S11B). In contrast, endogenous knockdown of
ZNF509 by siRNA decreased RB transcription (Figure 5E;
Supplementary Figure S11C). These results suggest that un-
like ZNF509L, which upregulates CDKN1A, ZNF509S1
inhibits cell proliferation by upregulating Rb.
ZNF509S1 binds theRB promoter by interacting withMIZF
We mapped the RB promoter cis-regulatory elements im-
portant for transcriptional activation by ZNF509S1. ChIP
assays of the endogenous RB promoter indicated that
ZNF509S1 bound to a distal promoter element (Figure 6A).
However, oligonucleotide pull-down assays showed that
ZNF509S1 by itself did not bind this element (Figure 6B),
suggesting that ZNF509S1 interaction with the RB pro-
moter might require another DNA binding protein. Since
MIZFwas shown to repress RB expression by acting on the
distal promoter (39), we investigated whether ZNF509S1
interacts with MIZF. Subsequent co-immunoprecipitation
and western blot analyses of HEK293 cells transfected with
FLAG-ZNF509S1 and/or His-MIZF expression vectors
did indeed reveal a ZNF509S1-to-MIZF interaction (Fig-
ure 6C). ChIP assays showed that while ZNF509S1 bind-
ing was increased by MIZF, MIZF binding was not af-
fected by ZNF509S1. ChIP-reChIP assays showed that co-
expressed ZNF509S1 and MIZF bound the promoter as a
complex. These results suggest that ZNF509S1 may be re-
cruited by MIZF bound to the distal RB promoter element
(Figure 6D).
Next, we investigated whether the protein–protein in-
teraction between ZNF509S1 and MIZF was functional.
Knockdown of ZNF509 decreased RB mRNA expression,
while knockdown of MIZF derepressed RB expression.
Knockdown of both ZNF509 and MIZF gave RB mRNA
expression similar to that ofMIZFknockdown (Figure 6E).
We also tested whether ectopic ZNF509S1 and/or MIZF
affect RB gene expression in the HCT116 p53+/+ cells
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Figure 4. ZNF509L interacts with MIZ-1 to additively activate CDKN1A transcription. (A) BiFC/FRET assays. CV1 cells were transfected with YN-
taggedMIZ-1 POZ andYC-tagged ZNF509 POZ domain pFPIA expression vector and analyzed with confocal microscopy. Negative controls; pFPIA-YN
and pFPIA-YC-ZNF590 POZ, pFPIA-YN-MIZ-1 POZ and pFPIA-YC. (B)Co-immunoprecipitation of ZNF509L andMIZ-1. Cell lysates prepared from
HEK293 cells transfected with FLAG-ZNF509L expression vector were immunoprecipitated using anti-FLAG or anti-MIZ-1 antibody and analyzed by
western blot using the antibodies indicated. (C)ChIP-reChIP assay of ZNF509L andMIZ-1 binding to theCDKN1A promoter. HCT116 p53+/+ cells were
transfected with FLAG-ZNF509L and immunoprecipitated with FLAG and/or MIZ-1 antibody. (D) Oligonucleotide pull-down assays of ZNF509L and
MIZ-1 binding to the CDKN1A promoter. HEK293 cells transfected with FLAG-ZNF509L and/or Myc-MIZ-1 expression vector were lysed, incubated
with oligonucleotides and NeutrAvidin-agarose beads, and precipitated by centrifugation. The precipitates were analyzed by western blot using antibodies
against FLAG or Myc. (E) RT-qPCR and western blot analysis of endogenous p21 expression in HCT116 p53+/+ cells transfected with siZNF509 RNA
and/or siMIZ-1 RNA. GAPDH, control; IP, immunoprecipitation; DNA-P, oligonucleotide pull-down assay. *P < 0.01.
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Figure 5. ZNF509S1 induces cell-cycle arrest by activating Rb expression in HCT116 p53+/+ cells. (A) Foci formation assay. Cells transfected with control
(upper row) or FLAG-ZNF509S1 expression (lower row) vectors were cultured in medium containing G418 and stained with 0.1% crystal violet. (B)
MTT assay of cells grown for 0–3 days. Cells were transfected with either control or ZNF509S1 expression vector and analyzed for cell growth. (C) Flow
cytometry analysis. Cells were transfected with ZNF509S1 expression vector for 24 h, stained with propidium iodide. (D) RT-qPCR and western blot
analysis of endogenous Rb expression in HCT116 p53+/+ cells transfected with a ZNF509S1 expression vector. (E)RT-qPCR and western blot analysis of
endogenous Rb expression in the HCT116 p53+/+ cells transfected with ZNF509 siRNA. GAPDH, control; Mock, no siRNA; N.C., scrambled siRNA.
*P < 0.01; n.s., not significant.
by RT-qPCR and western blot analysis. While ZNF509S1
upregulated RB, MIZF potently repressed transcription,
and that MIZF repression of RB was completely reversed
by upregulated ZNF509S1 (Supplementary Figure S12).
These data suggest that ZNF509S1 activates transcription
of RB by interacting with MIZF, and that this interaction
blocks repressor activity of MIZF. These results suggest
that ZNF509S1 may be recruited to bind MIZF and block
its repression potential, thus allowing derepression and up-
regulation of RB.
ZNF509 expression is low in various cancer tissues
We examined ZNF509 expression in various human can-
cer tissues by IHC of human tissue microarrays of paired
normal and cancer tissues using an anti-ZNF509 antibody.
ZNF509 was detected in both the nucleus and cytoplasm
(Supplementary Figure S1C). Compared to the ZNF509 ex-
pression level of paired normal tissues, ZNF509 expression
was lower in various cancer tissues of the adrenal grand,
colon, lung, skin, liver, ileum, prostate, paratoid grand and
uterus (data not shown). Expression levels of ZNF509 (both
L and -S) in paired cancer and normal tissues (colon, n= 33;
lung, n = 39) were analyzed by immunostaining. Depend-
ing on the expression levels of ZNF509, cancer (‘C’) tis-
sues were classified into three groups, as compared to nor-
mal (‘N’) tissues: N < C, N = C and N > C. IHC analysis
showed that ZNF509 expression was lower than normal tis-
sues in 27 out of 33 colon cancer cases (82%) and in 28 out of
39 lung cancer specimens (72%) (Figure 7, upper andmiddle
panels). Interestingly, while ZNF509 expression was high in
normal epidermal skin tissues (n = 12), its expression was
barely detectable in cancer skin tissues (n = 12) (Figure 7,
lower panel). These results may explain how various cancer
cells can proliferate rapidly in the absence of CDKN1A or
RB activation by ZNF509L or S, respectively.
DISCUSSION
When cells undergo DNA damage, alternative splicing of a
number of gene products, including Fas, TRAF2, APAF-
1, Bcl-x, Bak, Mcl-1 and caspases, plays an important role
in genotoxic responses (22,23). For example, Bcl-x, a p53
target gene, is alternatively spliced to a long isoform, Bcl-
xL, which is anti-apoptotic, and a shorter isoform, Bcl-xS,
which is pro-apoptotic.
ZNF509 expression is induced by DNA damage and is
also unique among POK family proteins in that two major
protein isoforms (ZNF509L and -S1), different in size and
slightly different in cellular localization, are generated by
alternative splicing (45). While we detected both ZNF509L
and -S1 in the cytoplasm and nucleus, ZNF509L was more
prominent in the nucleus (Supplementary Figure S1B and
C). Although both inhibited cell proliferation, they did so
by independentmechanisms. ZNF509L activated transcrip-
tion of CDKN1A, by binding to its promoter proximal
GC boxes and interacting with both MIZ-1 and the co-
activator p300 (Figure 8) to induceCDKN1A transcription.
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Figure 6. ZNF509S1 activates RB gene transcription by interacting and interfering with the transcriptional repressor MIZF. (A) ChIP assay of ZNF509S1
binding to the RB promoter. HCT116 p53+/+ cells were transfected with a FLAG-ZNF509S1 expression vector and immunoprecipitated with anti-FLAG
antibody. (B) GST or GST-ZNF509S1 recombinant proteins were incubated with oligonucleotides and NeutrAvidin-agarose beads, and precipitated by
centrifugation. The precipitate was analyzed by western blot using an antibody against GST. (C) Co-immunoprecipitation of ZNF509S1 and MIZF. Cell
lysates prepared from HEK293 cells transfected with FLAG-ZNF509S1 and/or His-MIZF expression vector were immunoprecipitated using anti-FLAG
or anti-His antibody and analyzed by western blot using the antibodies indicated. (D) ChIP-reChIP assay of ZNF509S1 and MIZF binding to the RB
promoter. HCT116 p53+/+ cells were transfected with FLAG-ZNF509S1 and/or His-MIZF expression vector and immunoprecipitated with FLAG or
His antibodies. (E) RT-qPCR and western blot analysis of endogenous Rb expression in HCT116 p53+/+ cells transfected with siZNF509 RNA and/or
siMIZF RNA. GAPDH, control; IP, immunoprecipitation; DNA-P, oligonucleotide pull-down assay. *P < 0.01; n.s., not significant.
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Figure 7. ZNF509 is expressed in epithelial cells of normal tissues, but is hardly detectable in most cancer tissues tested. IHC analysis of paired normal
(N) and cancer tissues (C) using antibodies against ZNF509 in colon (n = 33), lung (n = 39) and skin (not paired, normal n = 12, cancer n = 12). The
microscopy images were analyzed by ImmunoRatio software (http://imtmicroscope.uta.fi/immunoratio).
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Figure 8. Hypothetical model of DNA damage-induced cell-cycle arrest by ZNF509L and -S. p53, induced by genotoxic stress, binds to the ZNF509
distal promoter p53-response element (p53RE) to activate transcription of ZNF509. ZNF509L inhibits cell proliferation by transcriptional activation of
CDKN1A. Proximal promoter-bound ZNF509L andMIZ-1 recruit the co-activator p300 to activate CDKN1A transcription. p53 also activates CDKN1A
transcription by binding to the distal p53RE. ZNF509S gains access to the RB promoter by interacting with repressor MIZF to displace a corepressor and
recruits p300 to activate RB transcription. Increased p21 expression eventually inhibits phosphorylation of Rb and inhibits cell proliferation.
These proximal GC boxes are the target sites for not only
transcription factors like Sp1 but also several other POK
family members previously reported as proto-oncoproteins
(16,18,30,40,46). Also, oncoproteins that lack direct DNA
binding activity to theCDKN1A promoter, includingMYC,
BCL6 andGFI-1, interact withMIZ-1 to gain promoter ac-
cess and repress CDKN1A (6,11,13). ZNF509L may antag-
onize these transcriptional repressors through binding com-
petition atCDKN1A proximal promoter GC boxes. Ectopic
expression of ZNF509L most prominently increased G2-M
phase cell populations.
In contrast, ZNF509S1 inhibits cell proliferation by ac-
tivating Rb instead of CDKN1A. ZNF509S1 does not bind
DNA directly but interacts with MIZF to displace a core-
pressor and activate theRB promoter (Figure 8). Transcrip-
tional repression of RB by MIZF is important for oncoge-
nesis, cell adhesion, DNA repair and myogenesis. By inter-
actingwithMIZF, ZNF509S1may negatively regulate these
processes by antagonizing MIZF repression of RB (39).
We were intrigued by the fact that ZNF509L does not
activate RB transcription and ZNF509S1 does not activate
CDKN1A transcription. Because the two proteins are dif-
ferent only in the C-terminal zinc-finger region, that region
might be important in target gene selectivity and molec-
ular interaction with co-regulators like MIZ-1 or MIZF.
ZNF509S1 contains only one zinc-finger, and may not be
able to activateCDKN1A transcription due to its lack of do-
mains responsible for DNA-binding to the CDKN1A prox-
imal promoter or molecular interaction with MIZ-1. For
ZNF509L, it may not be able to interact with MIZF be-
cause the 6 additional zinc-fingers of ZNF509L may block
the interaction with MIZF.
The induction of p21 expression by ZNF509L results
in an accumulation of cells in G2/M, while the induction
of Rb by ZNF509S1 causes accumulation of cells in both
G0-G1 and G2-M phases. We next tested which of the
two effects (G0-G1 arrest by ZNF509S1 versus G2-M ar-
rest by ZNF509L) was dominant. ZNF509L decreased cell
proliferation more effectively, compared to ZNF509S1 in
HCT116 p53+/+ cells. However, ZNF509S1 decreased cell
proliferation more significantly, compared to ZNF509L, in
HEK293 cells. Accordingly, the contribution of ZNF509L
and -S1 in cell-cycle arrest may be cell type-dependent.
Interestingly, immunohistochemistry showed that
ZNF509 was expressed in epithelial cells of various normal
tissues, including normal colon crypts and normal skin
epidermis. However, ZNF509 was not expressed in the
various cancer tissues we tested, including the adrenal
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grand, colon, lung, skin, liver, ileum, prostate, parathyroid
gland and uterus. Moreover, ZNF509 expression was
not detected in 82% of colon cancer tissues and 72% of
lung cancer tissues. Consequently, loss of ZNF509 gene
expression may contribute to oncogenesis in these tissues.
Overall, our data suggest that the ZNF509 isoforms may
be potential tumor suppressors that facilitate cell-cycle
arrest.
DNA damage can induce either transient or prolonged
cell-cycle arrest, apoptosis and DNA repair, and p53 can
prolong cell-cycle arrest to allow time for repairing dam-
aged DNA (22,23). Cells stably overexpressing ZNF509L
or -S1 grow slowly, and have significantly increased G2-M
phase cell populations, without apoptosis. ZNF509 may ac-
complish prolonged cell-cycle arrest by increasing both p21
and Rb expression. Also, ZNF509S1 interacts with p53 and
inhibits its transcriptional activation ofPUMA (manuscript
in preparation). Thus, in normal tissues, ZNF509, as an ex-
ecutioner of p53, may prolong cell-cycle arrest (without cell
death) to secure time to repair DNA or elicit other DNA
damage responses, thus preventing oncogenic mutations.
In summary, ZNF509 controls the expression of the two
critical genes, RB and CDKN1A, which are both required
for differentiation, development and embryogenesis (47,48).
These features may explain in part why our multiple at-
tempts to generate ZNF509 knockout mice by homologous
recombination failed and we were not able to obtain het-
erozygous ZNF509 knockout mice from chimeras. Thus,
ZNF509 may be a regulatory protein essential for embry-
onic development, and ZNF509 haplodeficiency may be
lethal. Overall, our study suggests that ZNF509 is a novel
target gene of p53, having twomajor ZNF509 isoforms that
induce cell-cycle arrest without apoptosis.
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